Trademark: GALXC PLUS 2207245
Word
GALXC PLUS
ID
2207245
Trademark Type
Word
Status
Protected: Registered/protected
Application Date
14 July 2021
Registration Date
14 July 2021
Renewal Date
14 July 2031
Owner(s)
Service
Goods and Services:
Class 5:
Oligonucleotide compounds for use in targeted pharmaceutical therapies for the treatment of rare diseases, genetic disorders, cardiovascular diseases, and viral infections; oligonucleotide delivery agents for use in targeted pharmaceutical therapies for the treatment of rare diseases, genetic disorders, cardiovascular diseases, and viral infections; oligonucleotide compounds for use in the targeted delivery of RNAi therapy; oligonucleotide delivery agents consisting of compounds that facilitate the delivery of a wide range of pharmaceutical and therapeutic agents intravenously or subcutaneously for use in targeted pharmaceutical therapies for a wide range of medical purposes; drug delivery agents consisting of oligonucleotide compounds that facilitate the delivery of a wide range of pharmaceutical based therapies.
Oligonucleotide compounds for use in targeted pharmaceutical therapies for the treatment of rare diseases, genetic disorders, cardiovascular diseases, and viral infections; oligonucleotide delivery agents for use in targeted pharmaceutical therapies for the treatment of rare diseases, genetic disorders, cardiovascular diseases, and viral infections; oligonucleotide compounds for use in the targeted delivery of RNAi therapy; oligonucleotide delivery agents consisting of compounds that facilitate the delivery of a wide range of pharmaceutical and therapeutic agents intravenously or subcutaneously for use in targeted pharmaceutical therapies for a wide range of medical purposes; drug delivery agents consisting of oligonucleotide compounds that facilitate the delivery of a wide range of pharmaceutical based therapies.
Class 42:
Research and development of oligonucleotide compounds for use in targeted pharmaceutical therapies for the treatment of rare diseases, genetic disorders, cardiovascular diseases, and viral infections; research and development of pharmaceutical preparations for the treatment of disorders outside the liver; research and development of oligonucleotide compounds for targeted gene silencing; research and development of oligonucleotide drug delivery platforms for use in the treatment of rare diseases, genetic disorders, cardiovascular diseases, and viral infections.
Research and development of oligonucleotide compounds for use in targeted pharmaceutical therapies for the treatment of rare diseases, genetic disorders, cardiovascular diseases, and viral infections; research and development of pharmaceutical preparations for the treatment of disorders outside the liver; research and development of oligonucleotide compounds for targeted gene silencing; research and development of oligonucleotide drug delivery platforms for use in the treatment of rare diseases, genetic disorders, cardiovascular diseases, and viral infections.